IVVD

LIBERTY clinical trial will evaluate the comparative safety and tolerability of VYD2311 versus mRNA COVID-19 vaccine, as well as explore the safety and immunology of co-administered VYD2311 and mRNA COVID-19 vaccineDepending on study recruitment rate, Invivyd expects to report topline data from LIBERTY in Q3 2026, to accompany anticipated data from the pivotal DECLARATION clinical trialPrior exploration of monoclonal antibody (mAb) interaction with vaccine published here suggests a minimal clinical consequence to a similar interaction today, but could provide data to aid in potential product labelling language, if approved. This earlier work demonstrated an expected, modest reduction in vacc

NEW HAVEN, Conn., June 03, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on June 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 513,500 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $1.22, representing the closing price of Invivyd's common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first ann

DECLARATION is a Phase 3, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of VYD2311 in the prevention of symptomatic COVID-19 versus placebo, at three months, from a single intramuscular (IM) dose, with protection beyond three months anticipated  A second arm is evaluating monthly IM doses of VYD2311 versus placebo to demonstrate the safety and efficacy of more frequent dosing to support individual choice should at-risk people seek periodic extra protection from COVIDInvivyd previously conducted a pre-specified sample size re-estimation analysis designed to add statistical power robustness given future COVID event rate variability; upsizing was triggered an

NEW HAVEN, Conn., May 27, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that it will participate in upcoming investor events in June: 2026 Jefferies Global Healthcare Conference in New YorkFireside Chat Date & Time: Wednesday, June 3, 2026 4:55 p.m. ETLocation: New York, NYWebcast Link H.C. Wainwright "HCW @ Home" SeriesFireside Chat Date & Time: Monday, June 8, 2026 10:00 a.m. ETLocation: VirtualWebcast Link BTIG Infectious Disease Day 2026Date: Tuesday, June 16, 20261x1 Meetings Location: Virtual Live webcasts of the fireside chats will be available in the investor section of the company's website at investors.invivyd.com and will be archived following each eve

4 - Invivyd, Inc. (0001832038) (Issuer)

4 - Invivyd, Inc. (0001832038) (Issuer)

4 - Invivyd, Inc. (0001832038) (Issuer)

4 - Invivyd, Inc. (0001832038) (Issuer)

4 - Invivyd, Inc. (0001832038) (Issuer)

4 - Invivyd, Inc. (0001832038) (Issuer)

8-K - Invivyd, Inc. (0001832038) (Filer)

SCHEDULE 13G/A - Invivyd, Inc. (0001832038) (Subject)

S-8 - Invivyd, Inc. (0001832038) (Filer)

10-Q - Invivyd, Inc. (0001832038) (Filer)

8-K - Invivyd, Inc. (0001832038) (Filer)

Achieved Q1 2026 PEMGARDA® (pemivibart) net product revenue of $13.7 million, representing 22% growth versus Q1 2025 net product revenue of $11.3 millionInvivyd in vitro data showed continued neutralizing activity of pemivibart and VYD2311 against SARS-CoV-2 variant BA.3.2.2 ("Cicada"), confirming anticipated activityDECLARATION trial Independent Data Monitoring Committee (IDMC) ad hoc review of unblinded VYD2311 safety data resulted in IDMC recommendation for reduction of post-dose monitoring time from two hours to thirty minutesOperating expense increase quarter-over-quarter primarily attributable to DECLARATION pivotal program costs for VYD2311 for which top-line data is anticipated in Q3

Invivyd authors evaluated early side effects of prior low-dose investigational monoclonal antibody adintrevimab from the EVADE study, demonstrating minimal tolerability issuesResults allow for comparison to contemporary COVID-19 mRNA and protein vaccine tolerability, as well as epidemiologic extrapolation of systemic symptom days experienced via each approachUpcoming LIBERTY trial head-to-head study comparing safety and tolerability between VYD2311 and mRNA vaccine will build on these results in a rigorous, prospective fashion NEW HAVEN, Conn., May 11, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that a preprint of original research regarding COVID monoclonal antib

NEW HAVEN, Conn., May 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD), a biopharmaceutical company focused on delivering protection from serious viral infectious diseases, today announced that it will host a conference call on Thursday, May 14, 2026 at 8:30 a.m. ET to discuss its first quarter 2026 financial results and provide a corporate update.   Interested parties can register for the webcast via this link. Analysts wishing to participate in the question-and-answer session should use this link. A replay of the webcast will be available via the company's investor website approximately two hours after the call's conclusion. Those who plan on participating are advised to join 15

NEW HAVEN, Conn., May 05, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that on May 1, 2026, Invivyd granted 17 newly hired non-executive employees options to purchase an aggregate of 731,000 shares of its common stock, each as a material inducement for each employee's entry into employment with Invivyd. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd, Inc. 2026 Inducement Plan. The options have a per share exercise price of $1.52, representing the closing price of Invivyd's common stock on the grant date. Each option vests over four years, with 25% of the shares subject to such option vesting on the first anniv

Elia to speak at the premier gathering of policy makers, industry leaders, and health experts between 11:30 AM ET – 12:00 PM ET on April 21Event to be live streamed between 9:00 AM – 1:00 PM ET NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced that Marc Elia, Chairman of the Invivyd Board of Directors, is a featured speaker at the POLITICO Health Care Summit on Tuesday, April 21. During the session, Mr. Elia will frame the evolving landscape of viral disease prevention, including the role of monoclonal antibodies in keeping Americans healthy moving forward. "In American medicine, infectious disease prevention has historically involved substa

8-K - Invivyd, Inc. (0001832038) (Filer)

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can already provide sufficient statistical power to support the high end of anticipated VYD2311 efficacy Invivyd conducted a pre-specified sample size re-estimation analysis when 1,500 of 1,818 enrolled patients reached Day 45 of 90 total days (April 6th), designed to add robustness given future event rate variability; that upsizing was triggered and increases confidence in overall study statistical powerDECLARATION upsizing provides ~500 additional subjects and will likely shift study result timing modestly, by approximately two months, from original "

National education campaign aims to educate Americans about antibodies and their role in immune healthCampaign centerpiece, AntibodiesforAnyBody.com, offers an interactive immune health wellness assessment to empower people to better understand the relationship between their daily habits and immune health and wellness NEW HAVEN, Conn., April 07, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ:IVVD) today announced the launch of Antibodies for Any Body, a national education campaign designed to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in protecting against disease. The campaign launches in collaboration with renowned sk

DEFA14A - Invivyd, Inc. (0001832038) (Filer)

DEF 14A - Invivyd, Inc. (0001832038) (Filer)